MPR: Concise prescription and OTC drug information, side effects and interactions for medical professionals

RSS | Login | Register

Drug News

Feraheme safety update

February 08, 2010

AMAG Pharmaceuticals has provided a safety update on Feraheme (ferumoxytol injection) indicating that serious adverse events have been reported at a rate consistent with that contained in the Prescribing Information.

Oleptro approved for major depressive disorder (MDD)

February 03, 2010

The FDA has approved Oleptro (trazodone HCl extended-release tablets, from Labopharm), a once-daily formulation of trazodone, for the treatment of major depressive disorder (MDD) in adults.

Xiaflex approved for Dupuytren's contracture

February 03, 2010

Auxilium Pharmaceuticals announced the approval of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.

Restylane-L and Perlane-L dermal fillers approved

February 03, 2010

The FDA has approved Medicis' hyaluronic acid with lidocaine dermal fillers, Restylane-L and Perlane-L.

Juvéderm XC dermal filler approved

February 02, 2010

The FDA has approved Juvéderm XC (hyaluronic acid and lidocaine [preservative-free] injectable gel, from Allergan) dermal filler for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (eg, nasolabial folds).

Tysabri labeling to include safety information on risk of progressive multifocal leukoencephalopathy

February 05, 2010

The FDA has notified healthcare professionals and patients that the risk of developing progressive multifocal leukoencephalopathy (PML) increases with the number of Tysabri (natalizumab, from Biogen Idec) infusions received.

Zyprexa Prescribing Information updated for use in adolescents

February 01, 2010

Lilly and the FDA had notified healthcare professionals of changes to the Prescribing Information for Zyprexa (olanzapine) related to its indication for use in adolescents (13-17 years of age) for the treatment of schizophrenia and bipolar I disorder.

Orphan drug designation granted for aerosolized alpha1-proteinease inhibitor for alpha1-antitrypsin deficiency

February 08, 2010

Talecris Biotherapeutics was granted orphan drug designation by the FDA for the development of an aerosol formulation of alpha1-proteinease inhibitor to treat congenital alpha1-antitrypsin (AAT) deficiency.

Phase 2 study of tesetaxel for advanced melanoma

February 08, 2010

Genta Incorporated announced initiation of treatment in a Phase 2 trial of tesetaxel in advanced melanoma.

VOTRIENT

2/5/2010

Pazopanib 200mg, 400mg; tabs.

METOZOLV ODT

1/28/2010

Metoclopramide (as HCl) 5mg, 10mg; orally-disintegrating tabs; mint flavored.

VIBATIV

1/21/2010

Telavancin (as HCl) 250mg, 750mg; per vial; pwd for IV infusion after reconstitution and dilution; preservative-free.

ZENPEP 5000

1/14/2010

Lipase 5000 units, protease 17000 units, amylase 27000 units; del-rel caps.

SAPHRIS

1/7/2010

Asenapine 5mg, 10mg; sublingual (SL) tabs.

CerefolinNAC^® (L-methylfolate [Metafolin], methylcobalamin, N-acetylcysteine) Caplets: A Novel Approach to Early Memory Loss

January 27, 2010

New Product: Zenpep™ (pancrelipase) Delayed-Release Capsules

January 13, 2010

INVEGA^® SUSTENNA™ (paliperidone palmitate) Extended-Release Injectable Suspension for Acute and Maintenance Treatment of Schizophrenia

January 05, 2010

Antiemetic Medications

February 05, 2010

A list of drugs used for the treatment of nausea. The chart includes the formulations, strengths, and usual doses for each antiemetic drug product.

Catch-Up Immunization Schedule for Children

February 02, 2010

A catch-up immunization schedule for children 4 months to 18 years of age. The tables show minimum intervals between doses for children who have delayed immunizations.

Recommended Immunization Schedule for Ages 0 to 18 Years

January 21, 2010

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines for children through age 18 years.

Mood Disorder Treatments

January 12, 2010

Mood disorder treatments for bipolar disorder, major depressive disorder, treatment resistant depression, premenstrual dysphoric disorder, and others.

Antibiotic Formulations

January 12, 2010

Different formulations (tablets, capsules, liquid, or injection) of commonly prescribed antibiotics.

This February, MPR is honoring American Heart Month with a special drug information newsletter containing up-to-date information on cardiovascular disease management, research updates, and expert commentary on medical issues related to cardiovascular health to aid you in your practice.

View this month's MPR Seasonal Spotlight

Subscribe to the MPR Seasonal Spotlight

SPECIALTY

Coming Soon

TRY THIS OUT!

COMPARE FUNCTION

View different drug monographs in a side-by-side comparison
Compare any number of drug products
All fields within the drug monograph can be scanned easily

Compare Drugs Function Instructions

DOWNLOAD NOW

Download the MPR Mobile & Desktop Edition for free access to over 4,000 up-to-date, concise drug monographs on your computer or mobile device.

Updated Drugs

MAXIPIME

Infections & Infestations > Bacterial infections

Adverse reactions: encephalopathy added.

Updated: 2/9/2010

VAGIFEM

Ob/Gyn > Menopause and HRT

10microgram vaginal tab available.

Updated: 2/8/2010

VALSTAR

Neoplasms > Cytotoxic antibiotics

Monograph added.

Updated: 2/5/2010

IXIARO

Immune System > Immunization

Monograph added.

Updated: 2/4/2010

ZOLINZA

Neoplasms > Miscellaneous oncology agents

Precautions: QT prolongation removed. Interactions: concomitant warfarin: monitor PT, INR.

Updated: 2/3/2010

Click here to let us know what you are looking for.

Top 25 Searched Drugs

See all 25 »

MPR Weekly News Brief

Sign up for MPR's Weekly News Brief, available free to all visitors! Offerings include drug news and updates, new products, updated clinical charts, and more...